Podcasts about Glioblastoma

Show notes and links: www.chrisbeatcancer.com/how-jennifer-dickenson-healed-grade-4-glioblastoma-against-the-odds

Send us Fan MailJoin us as we return to our discussion on the fascinating ADePT trial in Glioblastoma brain tumours with the wonderful Dr Faye Robertson from the Western General Hospital, Edinburgh.We discuss how TGX-007 developed with TROGENIX with its super enhancers, dual payload and delivery system hopes to bring a break through in High grade Gliomas.We talk about how could this technology be 'rolled out' if successful. What level of success would be needed to develop the specialism for this kind of treatment.Could this therapy be adapted to be used in other cancer types such as pancreatic cancer etc ?With only 1 human trial patient clearly this is early days but we hope to follow this trial's progress on The Simply Oncology Podcast.Even if the survival outcomes of the trial were negative this trials move the dial in terms of what is possible from drug development and delivery.

Send us Fan MailSometimes we hear about a vision for a trial that is so novel and exciting that it takes you back a bit.This is one such moment.Join us as we talk to the amazing Dr Faye Robertson from the Edinburgh cancer Centre about the ingenious ADePT trial.DUAL PAYLOAD GENE THERAPY.Led by Trogenix and the University of Edinburgh, it tests a breakthrough "Trojan horse" gene therapy designed to destroy cancer cells and stimulate the immune system.TGX-007 is a drug developed with Tregonix that:How it Works: It uses dual-payload technology to deliver two distinct therapeutic agents:HSV-tk: Converts an orally administered antiviral drug (valaciclovir) into a toxic agent that directly kills proliferating tumour cells.IL-12: Acts as an immune-stimulating cytokine that turns the tumour into an in-situ vaccine, training the body's immune system to attack the cancer and prevent recurrence.We have had many false dawns in GBM trials but we are very excited by the results so far with TGX-007.Part 1 of 2 and this is a trial story we want to follow through.Enjoy!!!

Dr. Kyle Malone joins Dr. Kim Hellemans to discuss his research on glioblastoma, the most common and aggressive form of primary brain cancer in adults. [...]

·      Podcast Host and Interviewee:  Host: Maya GrahamInterviewee: Santiago Cepeda Description  Dr. Maya Graham interviews Dr. Santiago Cepeda on his recent Neuro-oncology article entitled "Prospective biopsy-controlled validation of an AI model for predicting glioblastoma infiltration: Results from the SupraGlio trial."

Host/Interviewee: ç, PhD Candidate, UT Health San Antonio Description: Shahad Abdulsahib discusses the GT-20 phase 1 clinical trial evaluating GNOS-PV01, a personalized multivalent neoantigen DNA vaccine administered following surgical resection and radiation in patients with MGMT unmethylated glioblastoma, with findings published in Nature Cancer on May 12th, 2026.

#182. Long Beach musician Dustin Lovelis immortalizes his late brother Graham with help from Seattle indie label Funny Goofy Records to release the debut LP from Uncle Grim and help raise awareness & funds to find a cure for Glioblastoma.Sponsored by DistroKid. Get 30% off your membership at distrokid.com/vip/independentmindedSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What do you do when a doctor tells you that you have 15 months to live and less than a 10% chance of surviving the next two years?In this episode of the Rollercoaster Podcast, I sit down with Doug Cartwright, a sales coach, entrepreneur, and one of the most spiritually grounded people I've ever met, who was diagnosed with Grade 4 Glioblastoma, the deadliest, most aggressive form of brain cancer, just weeks before we recorded this conversation.Doug walks us through the symptoms that were dismissed as anxiety, the emergency brain surgery that saved his life, and the vision he had that completely changed how he sees death, faith, and what it means to truly live.If you've ever faced a moment that shattered your sense of the future, this conversation will stay with you.Please consider supporting Doug's GoFundMe linked below:https://gofund.me/27a96d9edKey Moments:0:00 “I Thought I Was Going to Die Today”5:38 Waves of Panic & Impending Doom9:03 He Thought He Had DPDR Disorder14:09 The Phone Call That Saved His Life18:45 “My Life Will Never Be the Same”21:36 Living Like Every Day Could Be His Last25:18 The Power of Saying I Love You29:12 Brain Cancer Became His Greatest Test33:10 Can You Keep Your Heart Open in Hell?38:32 How to Change Without Trauma41:14 The Experimental Cancer Vaccine in Germany43:02 The Truth About Death Nobody Talks About44:13 The Message He Wants to Leave BehindConnect with Me: IG: @tyler.hall (https://www.instagram.com/tyler.hall/)Connect with Doug Cartwright:IG: doug_cartwright (https://www.instagram.com/doug_cartwright/)

Pastor Ken Keltner is Senior pastor of Brookside Baptist Church, Brookfield, WI. He's the speaker on The Word for Life radio broadcast which airs on WVCY. In James 1:2-3 it says, "My brethren, count it all joy when ye fall into divers temptations; Knowing this, that the trying of your faith worketh patience." The word "temptations" in this context is referring to testing or trials. It's a word we really don't like to hear. This passage indicates that the trying of our faith builds patience or endurance in us. Many times we read this quickly and we may talk about its meaning in application to others, but what about when the trials and tests hit you? What is your response when these trials all of a sudden seem to come from nowhere? You wonder, why is this happening to me? What have I done wrong? Do we really count it all joy when we go through such times? How do we respond? It's often said such trials can turn us bitter or better. So listen to this Crosstalk and find out how Pastor Keltner responded as he walks listeners through what occurred during events leading up to and beyond March 16, 2026. That's the day that Pastor Ken's wife Kathy went home to be with the Lord after battling Glioblastoma, an aggressive type of brain cancer. They were married over 42 years and amidst the extreme heartache, the Lord has shown himself faithful and is very much at work. More Information: brooksidebc.org ken.keltner@brooksidebc.org 262-783-6180

What are brain tumors, who is at risk, and what symptoms should you never ignore? In this episode of Baptist Health Talk, we break down the most searched questions about brain tumors, including common warning signs, treatment options, myths about cell phones, and why there is more hope today than ever before.Host Johanna Gomez is joined by Dr. Rupesh Kotecha, Chief of Radiosurgery at Baptist Health Miami Cancer Institute, and Dr. Evan Bander, neurosurgeon and co-director of the Pituitary Tumor Program at Baptist Health Miami Neuroscience Institute.In this episode, you'll learn:• What brain tumors are and how common they are • The difference between benign and malignant brain tumors • Whether cell phones or AirPods increase brain tumor risk • Symptoms such as persistent headaches, nausea, vision changes and seizures • When surgery, radiation, CyberKnife or other treatments may be used • Why multidisciplinary care matters for brain tumor patients • What glioblastoma is and why it receives so much attention • How palliative care supports quality of life • Where doctors see hope in newer treatment approachesSubscribe for more expert conversations on health, prevention and wellness from Baptist Health South Florida.Host:Johanna GomezAward-Winning Host & JournalistGuests:Rupesh Kotecha, M.DChief of Radiosurgery & Director of Central Nervous System MetastasisBaptist Health Miami Cancer InstituteEvan Bander, M.D.Neurosurgeon & Co-Director of the Pituitary Tumor ProgramBaptist Health Miami Neuroscience Institute If you found this episode helpful, you may also enjoy:Brain Tumors: Myths vs. FactsBrain AneurysmCaregiver 101: How to Support a Loved One with Brain Cancer

Pastor Ken Keltner is Senior pastor of Brookside Baptist Church, Brookfield, WI. He's the speaker on The Word for Life radio broadcast which airs on WVCY. In James 1:2-3 it says, "My brethren, count it all joy when ye fall into divers temptations; Knowing this, that the trying of your faith worketh patience." The word "temptations" in this context is referring to testing or trials. It's a word we really don't like to hear. This passage indicates that the trying of our faith builds patience or endurance in us. Many times we read this quickly and we may talk about its meaning in application to others, but what about when the trials and tests hit you? What is your response when these trials all of a sudden seem to come from nowhere? You wonder, why is this happening to me? What have I done wrong? Do we really count it all joy when we go through such times? How do we respond? It's often said such trials can turn us bitter or better. So listen to this Crosstalk and find out how Pastor Keltner responded as he walks listeners through what occurred during events leading up to and beyond March 16, 2026. That's the day that Pastor Ken's wife Kathy went home to be with the Lord after battling Glioblastoma, an aggressive type of brain cancer. They were married over 42 years and amidst the extreme heartache, the Lord has shown himself faithful and is very much at work. More Information: brooksidebc.org ken.keltner@brooksidebc.org 262-783-6180

Nearly two decades after the introduction of combined radiation therapy and temozolomide, the Stupp protocol remains the foundation of glioblastoma treatment. In this episode, Roger Stupp, MD, and Rimas Lukas, MD, take a look at how this regimen emerged as a durable standard of care and how clinical insights since then have refined its use. Dr. Stupp and Dr. Lukas walk through the modern care pathway for newly diagnosed glioblastoma and the clinical trial landscape. They dive into why survival gains remain limited and what may finally move the field forward.

“You're not broken… you're becoming.”  ~Tom SnyirIn this second half of our conversation, Tom and Heather Snyir share what life has looked like in the days, months, and years since their daughter Katie Rae went to Heaven.We talk about the realities of everyday grief - navigating the things people say, learning to live with “grief brain,” and facing simple questions that suddenly feel anything but simple.Tom and Heather also reflect on how grief has changed them - how it's reshaped their perspective, their relationships, and the way they move through the world.Tom opens up about his personal journey with PTSD, depression, and suicidal thoughts, and the people and faith that helped carry him through. He also shares about his devotional book, Branches of Grace, and the message of hope it offers to those walking through trauma and loss.This conversation is honest, practical, and full of insight for anyone navigating life after the loss of a child.Key Takeaways Presence matters more than words when supporting someone in grief  You are allowed to set boundaries and protect your heart  Grief changes you ... and that doesn't mean something is wrong  You don't have to walk through dark seasons alone  Healing and pain can exist side by side Resources & MentionsTom's book: Branches of Grace: Devotions from the Front Lines of Faith is available on Amazon.  Click HERE to find it.  Suicide & Crisis Lifeline (U.S.): Call or text 988I would love to hear your thoughts on the show. Click here to send me a message! (Though I read every message, I am unable to respond through this format.) ** IMPORTANT** - All views expressed by guests on this podcast are theirs alone, and may not represent the Statement of Faith and Statement of Beliefs of the While We're Waiting ministry.  We'd love for you to connect with us here at While We're Waiting! Click HERE to visit our website and learn about our free While We're Waiting Weekends for bereaved parentsClick HERE to learn more about our network of While We're Waiting support groups all across the country. Click HERE to subscribe to our YouTube channelClick HERE to follow our public Facebook pageClick HERE to follow us on Instagram Click HERE to follow us on Twitter Click HERE to make a tax-deductible donation to the While We're Waiting ministryContact Jill by email at:  jill@whilewerewaiting.org 

Shahad Abdulsahib discusses a phase 1 clinical trial of intracerebroventricular bivalent EGFR and IL13Rα2 CAR T cells for recurrent glioblastoma, published in Nature Medicine.

"God doesn't always remove the suffering—He enters into it with us.” In this first half of our conversation, Tom and Heather Snyir share the story of their daughter, Katie Rae—a creative, joyful teenager who made everyone around her feel like they were her best friend.Katie was diagnosed with leukemia at just four years old.  Tom and Heather share what it was like to navigate months of treatment, a bone marrow transplant, and the gift of more than a decade of remission.Then, as a teenager, Katie was diagnosed with glioblastoma, an aggressive and deadly form of brain cancer. In this episode, Tom and Heather begin sharing what that journey looked like for their family and how they walked through those difficult days together until Katie went to Heaven.Throughout this conversation, you'll hear how their faith was stretched and sustained—not through easy answers, but through God's presence in the middle of uncertainty.Resources & Mentions Tom Snyir's book: Branches of Grace: Devotions from the Front Lines of Faith - Available HERE.  Coming NextIn next week's episode, Tom and Heather share what life has looked like since Katie went to Heaven. We talk about grief in everyday life, how people respond to loss, and Tom shares more of his personal journey through PTSD, depression, and finding hope.I would love to hear your thoughts on the show. Click here to send me a message! (Though I read every message, I am unable to respond through this format.) ** IMPORTANT** - All views expressed by guests on this podcast are theirs alone, and may not represent the Statement of Faith and Statement of Beliefs of the While We're Waiting ministry.  We'd love for you to connect with us here at While We're Waiting! Click HERE to visit our website and learn about our free While We're Waiting Weekends for bereaved parentsClick HERE to learn more about our network of While We're Waiting support groups all across the country. Click HERE to subscribe to our YouTube channelClick HERE to follow our public Facebook pageClick HERE to follow us on Instagram Click HERE to follow us on Twitter Click HERE to make a tax-deductible donation to the While We're Waiting ministryContact Jill by email at:  jill@whilewerewaiting.org 

Hosts: Ed Jones (Owner – Nutrition World) & Clint Powell A variety of topics all related to living a healthy life Presented by: Nutrition World www.nutritionw.com Broadcasting from the Nooga Dentistry Studio www.noogadentistry.com Production of: Whitfield Media Group www.vitalhealthradio.com Show Summary & Time Stamps: Title: Saffron as “Nature's SSRI”, GLP-1 Side Effect Mitigation, Holistic Oral Health, & More [0:00:00] – Show Intro [0:01:44] – Ed's Fitness Goal & Using AI Ed's 4:00 a.m. gym routine and training structure. Goal: 14 weeks out from Chattanooga fitness/bodybuilding contest (men's classic over 50/55). Uses AI as a “thinking partner”: Uploads body and meal photos daily. Gets macro/meal feedback and accountability in ~7–8 minutes/day. Reports better progress in 3 weeks with AI than all of last year's prep. [0:05:08] – GLP‑1 / Weight‑Loss Drugs & Protein Strategy Conversation with Be Well Labs about GLP‑1/ozempic‑type drugs: ~1 in 8 people currently on weight‑loss meds; pill form may push toward 1 in 2. Concerns: long‑term side effects, muscle loss, “hijacking” normal physiology. Ed's mitigation tips for those on GLP‑1s: Aim for ~1 g protein per pound of body weight. Most will need two protein shakes/day plus weight training. [0:06:47] – Butyric Acid, Hydrogen Water & Sleep Gains Ed's last 3 weeks: More energy, best sleep/Oura Ring scores he's ever had (scores from ~71 → ~82). Two main changes: Butyric acid (from butter/fiber fermentation): 2 capsules in the morning. Supports gut lining, may have GLP‑1‑like effects. Hydrogen water: Uses a hydrogen bottle and tablets; must drink quickly after dissolving. Hypothesis: combination is improving gut health, inflammation, and overall well‑being. [0:10:18] – Dollar General “Stranded” Series New mini‑series concept: “What would Ed Jones do if stranded in a rural town and only had Dollar General for meals?” Finds ~12 foods (out of ~2000) he'd eat regularly. Message: even in limited environments (Dollar General, fast food), you can still find better choices. Content to appear on Instagram, Facebook, (possibly YouTube). [0:15:58] – Tallow, French Fries & Processed Carbs Rib & Loin (local BBQ restaurant) reportedly using beef tallow. Ed on fats: Prefers tallow (stable saturated fat) over seed/vegetable oils. Critiques decades of low‑fat dogma and resulting high‑carb intake and heart disease. Notes potato farmers discarding crops: Impact of GLP‑1 drugs on restaurant demand. Growing awareness of harm from processed carbs. Hydrogen‑rich “healing” waters story (German mine, Mexico, Japan) → dissolved molecular hydrogen theme. [0:22:17] – Oral Health, Tooth Powder & Mouth Microbiome Ed's dental routine: cleanings every 3 months. References his oral health e‑book (searchable via NutritionW.com). Product mention: Echo Dent Daily Care Tooth Powder: Chosen because it does not annihilate mouth bacteria. Key idea: chronic use of strong mouthwashes (even “natural” ones) may: Damage oral microbiome. Be linked to higher Alzheimer's risk via “bad” oral bacteria. Occasional disinfecting is fine (e.g., sore throat), but avoid twice‑daily “scorched earth” approach. [0:26:33] – Niacinamide, Glioblastoma & High Iron Study highlight: High‑dose niacin/niacinamide (B3) may support immune activity and short‑term outcomes in glioblastoma. Niacinamide boosts NAD (cellular energy/anti‑aging cofactor). Already used by dermatologists to help lower skin‑cancer risk. High iron / ferritin: Ferritin >100: likely inflammation or iron overload. Ferritin >200: pathological; associated with shorter lifespan. Action step: Test iron/ferritin (e.g., at Be Well Labs / beginwithlabs.com). If high, consider regular blood donation to lower iron. [0:34:42] – SSRIs & Antidepressants with Dr. Kurt Deering Guest: Dr. Curt Dearing, clinical pharmacist (30+ years). SSRIs discussed: Prozac, Celexa, Lexapro, Paxil, Zoloft. Effectiveness vs placebo: Placebo response in depression is high (~40%+). SSRIs only modestly better than placebo in many trials. Typical course: Weeks 1–2: patients often feel worse. Weeks 3–4: back to baseline. Weeks 4–6: if helpful, benefits show here. [0:40:44] – SSRI Side Effects, Withdrawal & Risks Common side effects: Nausea, vomiting, diarrhea, sweating, headaches. Sleep disturbance (insomnia or excessive sleepiness). Anxiety, jitteriness, tremors, dry mouth. Long‑term issues: Sexual dysfunction (very common). Weight changes (often weight gain). Withdrawal (if stopped abruptly): Anxiety, dizziness, flu‑like symptoms, insomnia. “Brain zaps” – electric‑shock sensations that strongly discourage abrupt stopping. Boxed warning: Increased suicidal thoughts/behaviors, especially 18–24‑year‑olds. [0:48:03] – Natural & Lifestyle Alternatives (Green Pharmacy) Strong caveat: never stop/taper SSRIs without coordinating with the prescribing clinician. Nutrient foundations: Vitamin D adequacy for mood and depression. Low‑dose lithium (as a micronutrient, e.g., lithium orotate): Supports brain health, reduces inflammation, may aid depression/anxiety/cognitive health. Omega‑3s, especially EPA, for mood support. Herbs & natural options: St. John's Wort, ashwagandha, saffron. Lifestyle interventions: Exercise (research shows it can match or beat standard depression care). Sunlight, sleep quality, mindfulness/prayer, overall holistic changes. Team approach: Add trainers, nutritionists, holistic practitioners alongside psychiatrists/MDs. [0:50:52] – Saffron as “Nature's SSRI” Clinical evidence: Meta‑analyses: saffron ≈ SSRIs in effect for mild–moderate depression. Faster onset (often 1–2 weeks). Side‑benefits: Heart health, anti‑inflammatory, lipid‑lowering. Cognitive support (including in Alzheimer's studies). PMS symptom relief. Eye health (age‑related macular degeneration support, intraocular pressure). Better sleep (duration and quality). Weight management (reduced appetite, body weight, waist circumference). Improved libido and sexual satisfaction (opposite of many SSRIs). [0:56:44] – Offers, Products & Closing WishGarden immune products: Immune boost for pregnancy. Kids' immune support formula (often mixed with honey for taste). Free bottle for the first 10 in‑store visitors mentioning the show (time‑limited). NoogaPodcasts.com: Clint promotes his local podcast network (crime, politics, adventure, health, faith, veterans, etc.). Fireside Herbicide: Plant‑desiccating herbicide that dehydrates weeds instead of poisoning soil. Less harmful to earthworms and soil life vs glyphosate products. Sign‑off: Radio airing on Sundays, podcast version (“Vital Health Radio”) drops Tuesdays. Thanks to listeners and mention of Nutrition World as primary sponsor. The post Radio Show / Podcast – April 5, 2026 first appeared on Vital Health Radio.

Discoveries being made by Yale Cancer Center experts could unlock treatments in other types of cancers in the future. Yale Cancer Center Visit: https://medicine.yale.edu/cancer/ Email: canceranswers@yale.edu Call 203-785-4095

Resveratrol + Copper Research, Plus Grain-Free Strategies for Stalled Weight Loss: Leyla Muedin, a registered dietitian nutritionist, answers listener emails. She reviews a small India study (BJC Reports, published September 30, 2025) in which 10 glioblastoma patients awaiting surgery received resveratrol (5.6 mg) and copper (560 ng) four times daily for about 11.6 days, compared with 10 controls; the combination generated reactive oxygen species that deactivated cell-free chromatin particles in the tumor microenvironment and reduced cancer hallmarks. Asked whether this could be prophylactic against cancer, she says it is unknown and requires replication in larger studies, advising supplement use be discussed with a practitioner. She then addresses grain elimination for stalled weight loss: replace grains with more meat and non-starchy vegetables, think beyond typical breakfast foods by using leftovers, and use small portions of starchy vegetables (e.g., squash or potato) if starch helps sleep. She recommends investigating root causes of anxiety and poor sleep and suggests moderation for foods like oatmeal.

Send us Fan MailPaper Discussed in this AI Journal Club:Artificial Intelligence-Based Digital Image Analysis for Assessing Ki67, P53, and PHH3 Expression in Glioblastoma Multiforme. Devrim T, Erkilinc G, Tuncer SS. J Coll Physicians Surg Pak 2026; 36(02):153-157Episode Summary: In this journal club deep dive, we step out of the theoretical future of AI and look at a direct, hard-data showdown between artificial intelligence and the human eye. We examine a groundbreaking 2026 study on Glioblastoma Multiforme (GBM) that forces us to ask an uncomfortable question: What happens when the AI and the human completely disagree? And more importantly, is it possible that the AI is detecting a biological reality that experienced human pathologists are entirely missing?In This Episode, We Cover:• The "Boss Battle" of Neuro-Oncology: Understanding Glioblastoma Multiforme (GBM), the most aggressive primary brain tumor in adults, and why precise prognosis dictates the entire treatment strategy.• The Big Three Biomarkers (The Speedometer, The Brakes, and The Neon Sign):    ◦ Ki67: The "speedometer" of the tumor, marking active cell proliferation.    ◦ p53: The "guardian of the genome," acting as the emergency brakes for damaged cells. In GBM, these brakes are often broken or mutated.    ◦ PHH3: A specific "neon mitosis tracker" that lights up dividing cells, offering a cleaner alternative to traditional manual counting.• The Showdown - Humans vs. AI: Two experienced pathologists go head-to-head with an AI digital image analysis system (QuantCentre module by 3DHISTECH) on 20 adult GBM cases, looking at both 1 mm² and 7 mm² tumor hotspots.• Round 1 - The Shocking Lack of Concordance: The AI and human pathologists had practically zero statistical agreement (Cohen's Kappa) on the raw numbers. The human eye acts interpretively, filtering out background noise, while the AI calculates literal pixel intensity.• Round 2 - The AI's "Aha!" Moment: Biologically, a high proliferation rate (Ki67) must correlate with high mitosis (PHH3). Human pathologists failed to find any statistically significant link between these markers. The AI, however, found strong, biologically accurate correlations between Ki67 and PHH3, and between PHH3 and p53.• The Future of the Lab: Why AI shouldn't replace pathologists, but rather serve as a hyper-sensitive tool to uncover hidden data patterns and personalize medicine. We also discuss the major roadblock preventing immediate clinical rollout: color standardization and image quality.Key Takeaway: The lack of agreement between humans and machines doesn't mean the AI is wrong. By successfully identifying crucial biological relationships that humans missed due to attentional fatigue and subjectivity, the AI proved its data might actually be closer to the biological truth than our current gold standard.Question of the Week for Our Trailblazers: Should we stop asking if the AI is as good as the human, and start asking if the human is actually precise enough to judge the AI? Let us know your thoughts!Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this Friday Headline Brief of The Wright Report, Bryan covers the partial government shutdown as Democrats refuse to fund DHS, President Trump's sweeping move to dismantle the legal foundation of climate regulations, and rising market volatility driven by the accelerating AI Revolution. Bryan then turns global, revealing new details about alleged foreign intelligence chatter involving Jared Kushner, a covert U.S. effort to move thousands of Starlink systems into Iran during mass protests, and a looming showdown over deported Venezuelan gang members after a federal judge orders them returned. He also sounds the alarm on China's expanding influence in Peru, covert corruption in Pacific island nations, suspicious seed packages arriving in American mailboxes, and the strategic mystery behind Beijing's 2 billion dollar renovation of New York's Waldorf Astoria. The episode closes with hopeful medical news from Canada, where researchers report a dramatic breakthrough in treating glioblastoma using high-dose vitamin B3.   "And you shall know the truth, and the truth shall make you free." - John 8:32     Keywords: February 13 2026 Wright Report, partial government shutdown DHS funding filibuster, Trump endangerment finding climate rollback, AI Revolution stock market volatility, Matt Schumer viral AI essay, Jared Kushner NSA intel Iran chatter, Starlink covert operation Iran protests, James Boasberg deported Venezuelan gang ruling, China Peru Chancay port control, CIA recruit Chinese officials purge Xi Jinping, Chinese seed packages brushing scam threat, Waldorf Astoria China renovation espionage concerns, vitamin B3 glioblastoma Canada study

Chris and Ben unpack a wild few days of NBA trades. Then later in the show Brandon Lisy AKA Whammy joins to discuss James Harden joining his beloved Cleveland Cavs. Gray for Glioblastoma - https://grayforglioblastoma.com/Glioblastoma is an aggressive, fast-growing, Grade IV malignant brain tumor, and the most common and deadliest primary brain cancer in adults. It's also one of the most expensive cancers to treat, often leaving patients and families with major financial hardship on top of the burdens of the disease.Swish FM is Chris Wendelken and Ben Craw.SWISH FM:Email: swishfmradio@gmail.comTwitter: @SwishFMRadioInstagram: @SwishFMRadioApple: apple.co/2NXjMP8Spotify: spoti.fi/2T7ZmjYMUSIC:Artist: LetheretteAlbum: Brown Lounge, Vol. 1Title: Montego FuzzLabel: WulfApple: apple.co/2kyOBLOSpotify: spoti.fi/2kqAhoT Hosted on Acast. See acast.com/privacy for more information.

VIDEO & AUDIO ON PATREON It's S-S-Seeking Sunday! Ben here. Today, Jacques, Hesse, and I take a deep dive into the Straight Acting Brotherhood, a members-only club for men who are into men and... drop shipping. Before emailing the organization's spokesperson in a truly desperate attempt to join, we try to figure out what this group actually offers and why certain gay men are drawn to it in the first place. Is it the promise of business expertise and elite networking opportunities? Or is it the allure of high-effort hustlepreneur drag? Also I show Hesse and Jacques my new treadmill and sauna and Jacques tell us why you will get blocked if you DM him about his hair. Intro & Outro– Slayrizz, Imagine If

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and trends shaping the industry landscape, offering insights into how companies are navigating scientific, regulatory, and market challenges.The pharmaceutical and biotech sectors are in a dynamic period marked by substantial scientific advancements and strategic developments. Among the key players, Sanofi is demonstrating resilience despite geopolitical challenges affecting vaccine policies in the United States. The company's CEO, Paul Hudson, remains optimistic about their vaccine portfolio even amidst a slight downturn in vaccine sales, which decreased by 2.5% in the fourth quarter of 2025 and 1.2% for the entire year. This scenario highlights the broader industry challenge of maintaining focus on long-term goals while adapting to fluctuating market dynamics. In parallel developments, Sanofi has decided to discontinue its efforts to develop a next-generation mRNA seasonal flu vaccine after two and a half years of attempting to revolutionize flu prevention with mRNA technology. This halt underscores the challenges associated with mRNA vaccines in addressing seasonal flu strains despite their success during the COVID-19 pandemic.Roche is gearing up for an eventful 2026 with ten new molecules entering late-stage testing. Potential launches, including the breast cancer candidate giredestrant, are on the horizon. However, they face challenges as their eye drug Vabysmo underperformed against projections, and their Tecentriq failed in an early lung cancer study. These outcomes underscore the inherent risks of pharmaceutical research and development, illustrating how clinical trial results can substantially impact company trajectories. Additionally, Roche has decided to remove Kiniksa's fibrosis drug from its Phase 2 pipeline as part of a broader quarterly review. This decision reflects ongoing reassessment activities by pharmaceutical companies aiming to optimize resource allocation and focus on promising candidates. Roche also unveils its ambition to become a major player within obesity treatment markets—directly challenging industry leaders like Novo Nordisk—by securing top-three positioning during company earnings presentations last year—a strategic pivot towards obesity reflecting broader industry trends focusing increasingly upon metabolic disorders amid rising global prevalences thereof worldwide today.In a notable achievement, Tenpoint Therapeutics has secured FDA approval for Yuvezzi, an innovative vision-correction eye drop addressing presbyopia—a common age-related condition. The approval stems from combining two existing eye drop formulations, showcasing how repurposing compounds can lead to new therapeutic options. With $235 million raised to support its Q2 launch, Tenpoint's confidence in Yuvezzi's market potential is clear.The biopharma merger and acquisition landscape is evolving as companies shift focus from acquiring blockbuster drugs to enhancing capabilities across the drug development continuum. This strategic pivot reflects a more integrated approach to growth, aimed at building comprehensive portfolios that address various stages of drug commercialization and development.AstraZeneca has announced a substantial $15 billion investment in China by 2030 to expand its cell therapy and radioconjugate capabilities. This move underscores China's strategic importance as a biopharma market and highlights AstraZeneca's commitment to leveraging innovative technologies to enhance therapeutic offerings. AstraZeneca is making significant strides with this investment aimed at advancing its capabilities in China through 2030. This strategic move highlights the growing importance of personalized medicine and targeted therapies in emerging markets like China.ReguSupport the show

First, Chris speaks with Catherine and Laila Kennedy about running in the 2026 Paris Marathon on April 12th in memory of their brother-in-law, Evan Knaff, and raising funds and awareness for the Glioblastoma Research Organization. And then Ben joins the show to catch up on the NBA.Links below for Catherine and Laila's fundraisers—if you're in a position to help, your support is greatly appreciated!Catherine Kennedy - https://fundraise.gbmresearch.org/campaign/748102/donateLaila Kennedy - https://fundraise.gbmresearch.org/campaign/748093/donateGray for Glioblastoma - https://grayforglioblastoma.com/Glioblastoma is an aggressive, fast-growing, Grade IV malignant brain tumor, and the most common and deadliest primary brain cancer in adults. It's also one of the most expensive cancers to treat, often leaving patients and families with major financial hardship on top of the burdens of the disease.Swish FM is Chris Wendelken and Ben Craw.SWISH FM:Email: swishfmradio@gmail.comTwitter: @SwishFMRadioInstagram: @SwishFMRadioApple: apple.co/2NXjMP8Spotify: spoti.fi/2T7ZmjYMUSIC:Artist: LetheretteAlbum: Brown Lounge, Vol. 1Title: Montego FuzzLabel: WulfApple: apple.co/2kyOBLOSpotify: spoti.fi/2kqAhoT Hosted on Acast. See acast.com/privacy for more information.

Bill Cadwallader explores rising brain tumors, infertility, and other illnesses linked to EMFs from cell phones and wireless devices. #EMFs #BrainHealth #RadiationRisks #HealthTalks

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Glioblastoma⁠⁠⁠ ⁠from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

How do most organisms in the natural world communicate? It's through the language of chemistry. Scripps Institution of Oceanography marine biologists Bradley Moore and Natalie Grayson explore how ocean life uses molecules as a language. Examples include a pigment that lets squid and octopus change color for camouflage, a coral and its microbial partners that produce biologically active compounds, and a chemical now in phase three human clinical trials to treat glioblastoma, an aggressive cancer of the brain. Their research has applications for new materials in biotech, and improving the food supply and human health. Series: "Jeffrey B. Graham Perspectives on Ocean Science Lecture Series" [Science] [Show ID: 41190]

How do most organisms in the natural world communicate? It's through the language of chemistry. Scripps Institution of Oceanography marine biologists Bradley Moore and Natalie Grayson explore how ocean life uses molecules as a language. Examples include a pigment that lets squid and octopus change color for camouflage, a coral and its microbial partners that produce biologically active compounds, and a chemical now in phase three human clinical trials to treat glioblastoma, an aggressive cancer of the brain. Their research has applications for new materials in biotech, and improving the food supply and human health. Series: "Jeffrey B. Graham Perspectives on Ocean Science Lecture Series" [Science] [Show ID: 41190]

How do most organisms in the natural world communicate? It's through the language of chemistry. Scripps Institution of Oceanography marine biologists Bradley Moore and Natalie Grayson explore how ocean life uses molecules as a language. Examples include a pigment that lets squid and octopus change color for camouflage, a coral and its microbial partners that produce biologically active compounds, and a chemical now in phase three human clinical trials to treat glioblastoma, an aggressive cancer of the brain. Their research has applications for new materials in biotech, and improving the food supply and human health. Series: "Jeffrey B. Graham Perspectives on Ocean Science Lecture Series" [Science] [Show ID: 41190]

How do most organisms in the natural world communicate? It's through the language of chemistry. Scripps Institution of Oceanography marine biologists Bradley Moore and Natalie Grayson explore how ocean life uses molecules as a language. Examples include a pigment that lets squid and octopus change color for camouflage, a coral and its microbial partners that produce biologically active compounds, and a chemical now in phase three human clinical trials to treat glioblastoma, an aggressive cancer of the brain. Their research has applications for new materials in biotech, and improving the food supply and human health. Series: "Jeffrey B. Graham Perspectives on Ocean Science Lecture Series" [Science] [Show ID: 41190]

How do most organisms in the natural world communicate? It's through the language of chemistry. Scripps Institution of Oceanography marine biologists Bradley Moore and Natalie Grayson explore how ocean life uses molecules as a language. Examples include a pigment that lets squid and octopus change color for camouflage, a coral and its microbial partners that produce biologically active compounds, and a chemical now in phase three human clinical trials to treat glioblastoma, an aggressive cancer of the brain. Their research has applications for new materials in biotech, and improving the food supply and human health. Series: "Jeffrey B. Graham Perspectives on Ocean Science Lecture Series" [Science] [Show ID: 41190]

Glioblastoma has a long-term survival rate under 1% at ten years. After decades of research focusing primarily on mutation-targeted therapies, median survival has improved by only a few months. Dr. Tomás Duraj believes there's a better path forward.Dr. Duraj is a physician-scientist at Boston College working on the metabolic vulnerabilities of cancer. In this Metabolic Health Summit presentation, he outlines a clinical framework for studying ketogenic metabolic therapy — one built on biomarker-driven protocols, not dietary guesswork.The core argument: cancer cells depend on specific metabolic pathways for survival. Block those pathways while providing alternative fuels to healthy cells, and you create a therapeutic window that most tumors can't escape.Why cancer cells metabolically resemble organisms from 2 billion years agoThe limits of the somatic mutation theory and why most targeted gene therapies have underdeliveredSubstrate level phosphorylation vs. oxidative phosphorylation — and why the distinction mattersThe Glucose-Ketone Index as a measurable, actionable biomarkerThe press-pulse strategy: sustained metabolic pressure paired with targeted interventionsHow to protect healthy tissue before targeting tumor metabolismRepurposed pharmacological approaches and the need for publicly funded clinical trialsThe case for small, non-randomized pilot studies with highly motivated patientsMetabolic therapy represents the future of medicine: a coherent clinical strategy grounded in decades of research and increasingly recognized by physicians and scientists across disciplines. For practitioners seeking complementary approaches that extend the reach of oncological therapeutics, this presentation lays out a practical roadmap for integrating emerging insights with standard care.✅Genova Connect – Get 15% off any test kit with code METABOLICLINK here.✅ iRestore - Get a huge discount on the iRestore Illumina Face Mask when you use the code METABOLICLINK here.✅Piquelife.com - Get the Pu'er Bundle for 20% off here.In every episode of The Metabolic Link, we'll uncover the very latest research on metabolic health and therapy. If you like this episode, please share it, subscribe, follow, and leave us a comment or review on whichever platform you use to tune in!You can find us on all your major podcast players here and full episodes are also up on our Metabolic Health Summit YouTube channel!Find us on social: Instagram Facebook YouTube LinkedIn Please keep in mind: The Metabolic Link does not provide medical or health advice, but rather general information that does not serve as a substitute for a licensed healthcare professional. Never delay in seeking medical advice from an appropriately licensed medical provider for any health condition that you may have.

Depo-Provera was approved in 1992 by U.S. regulators. About 1 in 4 sexually active women in the United States have used the shot at some point, according to the U.S. Centers for Disease Control and Prevention (CDC). Meningiomas are common intracranial tumors with a female predominance. In fact, they are the most common primary brain tumor in women, with an incidence of approximately 12.76 per 100,000 in the general female population. The vast majority of these tumors are benign (World Health Organization [WHO] grade 1) while 15% to 20% of these tumors can behave atypically (WHO grade 2) and rarely, in 1% to 2% of cases, these tumors can be malignant (WHO grade 3). We covered the relationship between Depo-Provera, as a contraceptive agent, and brain meningiomas back in March 2024. With the increase in data, the ACOG released a patient centered counseling tool titled, “Counseling Patients on Birth Control Injection and Meningioma”. The most recent update on this story comes from the FDA, which has granted a medication label change to Depo-Provera (Pfizer) warning of this association. Even though association does not prove causation, the association between depo and meningiomas seems strong (with new data from the US). Does this warning extend to other progestins? Listen in for details. 1. https://podcasts.apple.com/us/podcast/dr-chapas-obgyn-clinical-pearls/id1412385746?i=10006508795722. ACOG's “Counseling Patients on Birth Control Injection and Meningioma” 3. https://www.statnews.com/pharmalot/2025/12/17/fda-pfizer-contraception-cancer-preemption-depoprovera/4. Xiao T, Kumar P, Lobbous M, et al. Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US. JAMA Neurology. 2025;82(11):1094-1102. doi:10.1001/jamaneurol.2025.3011.5. de Dios E, Näslund O, Choudhry M, et al.Prevalence and Symptoms of Incidental Meningiomas: A Population-Based Study.Acta Neurochirurgica. 2025;167(1):98. doi:10.1007/s00701-025-06506-7.6. Schaff LR, Mellinghoff IK.Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023;329(7):574-587. doi:10.1001/jama.2023.0023.7. BMJ 2024; 384 doi: https://doi.org/10.1136/bmj-2023-078078 (Published 27 March 2024) Cite this as: BMJ 2024;384:e078078

Chris and Ben talk about the Knicks beating the Spurs to win the NBA Cup. And then they catch up on the incredible life of friend, listener and Swish FM guest, Evan Knaff, who passed away on December 9th, 2025.Gray for Glioblastoma - https://grayforglioblastoma.com/Glioblastoma is an aggressive, fast-growing, Grade IV malignant brain tumor, and the most common and deadliest primary brain cancer in adults. It's also one of the most expensive cancers to treat, often leaving patients and families with major financial hardship on top of the burdens of the disease.Cystic Fibrosis Foundation - https://www.cff.org/Cystic fibrosis is a genetic disorder that affects the lungs, pancreas, and other organs. There are close to 40,000 children and adults living with cystic fibrosis in the United States and an estimated 105,000 people have been diagnosed with CF across 94 countries. CF can affect people of every racial and ethnic group.If you're in a position to help, your support is greatly appreciated!Swish FM is Chris Wendelken and Ben Craw.SWISH FM:Email: swishfmradio@gmail.comTwitter: @SwishFMRadioInstagram: @SwishFMRadioApple: apple.co/2NXjMP8Spotify: spoti.fi/2T7ZmjYMUSIC:Artist: LetheretteAlbum: Brown Lounge, Vol. 1Title: Montego FuzzLabel: WulfApple: apple.co/2kyOBLOSpotify: spoti.fi/2kqAhoT Hosted on Acast. See acast.com/privacy for more information.

Family, this week on Queer News Anna DeShawn continues to bring you the stories that matter most to our community. In top news, Trans Up Front Illinois received a big grant from Lady Gaga's foundation. In politics, we have a disappointing update on the U.S military ban. In culture and entertainment, Jason Collins shares that he has been diagnosed with stage four brain cancer, Cynthia Erivo makes Golden Globe history, and the Teen Vogue X GLAAD 20 under 20 list is out! Let's get into it. Want to support this podcast?

A new technique for delivering radiation to glioblastoma brain tumors may allow doctors to use much higher doses while preserving healthy brain tissue. UT Health San Antonio's Andrew Brenner, MD, PhD, says this may give patients more time.

AI may be able to help in the fight against cancer. Kun-Hsing Yu, associate professor in the department of biomedical informatics at Harvard Medical School, looks into how it can help. Kun-Hsing “Kun” Yu, M.D., Ph.D., is an Associate Professor in the Department of Biomedical Informatics at Harvard Medical School. He pioneered the first fully […]

My guest is Dr. David Fajgenbaum, MD, professor of translational medicine and human genetics at the University of Pennsylvania. He explains how, unbeknownst to most doctors, many approved medications can successfully treat or even cure diseases other than the ones they are typically used to treat. He shares his story of escaping death from Castleman's disease by discovering a life-saving treatment using repurposed drugs that were approved for other purposes. Our conversation explores how researchers, physicians, and you—the general public—can explore novel treatments and cures to conditions the medical profession has deemed untreatable, including cancers. We also discuss the crucial role of mindset in battling diseases and the lesser-known use of compounds to promote health and longevity. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AGZ by AG1: https://drinkagz.com/huberman Eight Sleep: https://eightsleep.com/huberman Rorra: https://rorra.com/huberman David: https://davidprotein.com/huberman Function: https://functionhealth.com/huberman Timestamps (0:00) David Fajgenbaum (4:06) Self-Agency in Healthcare; New Uses for Old Medicines (6:44) Other Uses of Aspirin & Viagra; Drug Development & Approved Use (8:53) Lidocaine & Breast Cancer; Pharmaceutical Companies & Incentives (11:36) Sponsors: Eight Sleep & Rorra (14:16) Pharmaceutical Companies, Patents & New Uses; Lithium (18:40) Tools: Finding Reliable Health Sources, Asking Questions & Disease Organizations; DADA2 Treatment (21:53) Medical Community & Connections; Integrated Medical Databases (24:36) Drug Repurposing, Thalidomide, Pembrolizumab (28:45) Medical Research Databases, Mapping Disease Connections (33:51) Every Cure Database & Programs, Bachmann-Bupp Syndrome; Colchicine & Heart Disease (37:57) Sponsors: AGZ by AG1 & David (40:41) David's Medical & Career Journey, Glioblastoma, Castleman Disease (49:10) Autoimmune Disease, Driven Personality, Stress & Immune System (52:52) Castleman Disease, Treatment, Chemotherapy (55:54) Physician Continuing Education, Santa Claus Theory of Civilization; Science Collaboration (1:03:32) Medical School, Relapse & “Overtime”, Finding a New Treatment, Rapamycin (1:12:46) Sport, Football & Resilience; Challenge & Personal Growth, Family (1:18:41) Sponsor: Function (1:20:29) Social Support; “Overtime”, Gratitude (1:23:19) Business School, Castleman Disease Treatment; Repurposing Drugs & AI (1:28:29) Drug Repurposing, POEMS Syndrome; Mitigating Risk (1:35:32) Nicotine, Compounds for Preventive Health; GLP-1 Agonists (1:40:51) Bioprospecting, Drug Development; AI, Prioritization & Novel Connections (1:46:18) Healthcare & Children; Hope, Action & Impact Circuit; Challenge & Super-Agers (1:52:50) Get Involved with Every Cure (1:56:20) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Curing with Sound, we explore a groundbreaking approach to one of medicine's toughest cancers, glioblastoma (GBM), with Michael Canney, PhD, Chief Scientific Officer at Carthera. GBM is the most aggressive form of brain cancer, notoriously hard to treat because the blood-brain barrier (BBB) blocks many life-saving drugs from reaching tumor cells. With survival rates of just one to two years, new approaches are urgently needed. Dr. Canney shares how Carthera's SonoCloud-9, an implantable, therapeutic ultrasound device, temporarily opens the BBB and enhances the delivery of circulating drugs to the brain. He also discusses the SONOBIRD clinical trial, comparing the use of Carthera's SonoCloud-9 device combined with chemotherapy to standard-of-care therapies in patients with recurrent GBM. Discussion highlights: Phase III SONOBIRD Trial: The largest clinical trial in Carthera's history, enrolling 560 patients across the United States and Europe. The trial's goal is to demonstrate a survival advantage for patients with recurrent GBM when BBB opening is combined with the delivery of carboplatin chemotherapy, as compared with standard of care. Revolutionizing Drug Delivery: How SonoCloud-9 opens the BBB to increase carboplatin concentrations five- to seven-fold, potentially unlocking the full potential of existing cancer drugs that previously couldn't reach brain tumors. EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/

BUFFALO, NY – October 14, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on October 13, 2025, titled “Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields.” The study, led by Hugo Jimenez from Wayne State University School of Medicine, Karmanos Cancer Institute, introduces a novel treatment approach for glioblastoma, an aggressive and often treatment-resistant brain cancer. The findings open a new potential path for patients who currently have limited therapeutic options. The approach uses a device developed by TheraBionic that delivers extremely low levels of radiofrequency electromagnetic fields, tuned to frequencies associated with glioblastoma. In laboratory experiments, this therapy significantly slowed the growth of multiple glioblastoma cell lines. It was especially effective against tumor stem cells, which are known to resist standard treatments and drive cancer reappearance. Researchers also found that the treatment's effects depend on a calcium channel in tumor cells known as Cav3.2 (CACNA1H). When this channel was blocked, the therapy lost its effectiveness, highlighting the channel's essential role in how tumor cells respond to the signal. The therapy also disrupted the process of cell division by interfering with the mitotic spindle, a structure critical for cell replication. This disruption was associated with changes in the expression of genes that regulate cell division, particularly those involved in the “Mitotic Roles of Polo-Like Kinase” pathway. These effects were specific to tumor-targeted frequencies, as non-matching signals had no measurable impact. The study also includes data from two patients with difficult-to-treat brain tumors who received the therapy through compassionate use. One patient with recurrent glioblastoma showed signs of clinical and radiographic improvement after one month of treatment. Another patient with oligodendroglioma tolerated the therapy well and had stable disease during follow-up imaging. Neither patient experienced serious side effects, further supporting the safety of the therapy. “There was evidence of clinical and radiological benefit in a 38-year-old patient with recurrent GB and evidence of safety and feasibility in a 47-year-old patient with oligodendroglioma.” This is the first study to demonstrate that tumor-specific radiofrequency therapy can suppress both tumor growth and cancer stem cells in glioblastoma. Similar results had previously been observed in liver and breast cancers. These findings contribute to the growing body of evidence supporting a new class of systemic, non-toxic cancer therapies. Further clinical trials will be crucial to confirm these results and fully assess the potential of this approach for treating brain cancer. DOI - https://doi.org/10.18632/oncotarget.28770 Correspondence to - Hugo Jimenez - hugo.jimenez@wayne.edu Abstract video - https://www.youtube.com/watch?v=uxYnWcNKYfg Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28770 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, oncology, amplitude-modulated radiofrequency electromagnetic fields, glioblastoma, TheraBionic, CACNA1H, Cav3.2 To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Heal The Soul, Heal The Body: Immersive Reality For Interfaith Rooms Many interfaith rooms in hospitals are either too specific to one religion or not specific enough to feel sacred. Our experts this week discuss how immersive reality and Disney technology can help give patients the religious rooms they crave while fighting for their lives. Glioblastoma: The Aggressive Brain Cancer That Has A Sweet Tooth Glioblastomais an aggressive form of brain cancer that leaves many patients withonly tw years to live, if they're lucky. One obstacle researcherface is understanding how the tumors grow so fast. Our expert explains his breakthrough research on the cancer's metabolic habits and how it'll help increase life expectancy for patients. Medical Notes: Binge-Watching Is Good For Your Brain, How To Detect Cancer At Home, And Breaking Bad Fitness Habits Learn more about your ad choices. Visit megaphone.fm/adchoices

Glioblastoma is an aggressive form of brain cancer that leaves many patients with only two years to live, if they're lucky. One obstacle researchers face is understanding how the tumors grow so fast. Roger Holzberg explains his breakthrough research on the cancer's metabolic habits and how it'll help increase life expectancy for patients. Learn More: https://radiohealthjournal.org/glioblastoma-the-aggressive-brain-cancer-that-has-a-sweet-tooth Learn more about your ad choices. Visit megaphone.fm/adchoices

Summary of the YouTube Video Featuring Brandon McBee on the Strong Dad's PodcastIntroduction and ContextThe video begins with a brief introduction by the Merrill, who reflects on his recent diagnosis of cancer, Glioblastoma. Merrill expresses gratitude for the audience's continued supportand an explanation for the delay in this particular episode. The show features Brandon McBee, an experienced educator and assistant principal at Harrison Junior School in Harrison, Ohio, who shares insights into the importance of father involvement in children's education.Importance of Father's RoleBrandon emphasizes that the presence of a father figure or a positive male role model significantly influences a child's development. He references statistics to underline the negative outcomes for children when fathers are absent, such as increased behavioral problems and lower academic performance. He notes that the role of dads in education is crucial, and their active engagement can make a significant difference in a child's life.Changes in Education Over TimeBrandon discusses how his role in education has evolved over his 15 years in the field, particularly due to the COVID-19 pandemic, which transformed the educational landscape. He shares experiences from his first year in administration when he had to manage contact tracing and other pandemic-related challenges. The conversation touches on the cyclical nature of educational trends, where old strategies re-emerge under new names.Technology in EducationThe discussion highlights the impact of technology on students' learning experiences. Brandon notes that while technology has benefits, over-reliance on it can lead to challenges like cyberbullying and diminished social skills. He advocates for more face-to-face interaction and physical activity, encouraging parents to limit access to devices for young children.The Evolving Role of SchoolsBrandon indicates that while schools have adapted by integrating technology, there is a growing conversation about the need to return to more traditional teaching methods. Educational PhilosophyBrandon reflects on educational reforms, cautioning against the constant changes driven by political agendas. He stresses that while teaching methods may change, the fundamentals of education and human interaction remain constant.Engaging with ChildrenThe discussion pivots towards how fathers can actively engage with their children. Brandon offers practical advice for dads, encouraging them to start small and find common interests to connect with their kids. Navigating ExpectationsBrandon discusses the balance of setting expectations for children. He advocates for clear communication and consistency regarding what is expected from kids in terms of behavior and academic performance, emphasizing the need for flexibility based on individual strengths and weaknesses.Challenges of ParentingThe video addresses the pressures parents face in raising children amidst societal expectations. Brandon reflects on the importance of resilience and teaching children how to handle failure. The Role of LeadershipBrandon shares insights into leadership, both in education and parenting. He encourages dads to model good leadership qualities, such as empathy, understanding, and teamwork. rocksolidfamilies.orgSupport the show#Rocksolidfamilies,#familytherapy,#marriagecounseling,#parenting,#faithbasedcounseling,#counseling,#Strongdads,#coaching,#lifecoach,#lifecoaching,#marriagecoaching,#marriageandfamily,#control,#security,#respect,#affection,#love,#purpose,#faith,#mastersofdisaster,#storms,#disasterrelief,#tornados,#hurricanes,#floods

SOURCES: The Female Family Annihilator - Hannah Scott, Katie Fleming, 2014Why did this TikTok influencer kill her husband and two children? | The IndependentAutopsy Results in Madbury, New Hampshire Deaths Investigation

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Edward Chang is a neurosurgeon, scientist, and a pioneering leader in functional neurosurgery and brain-computer interface technology, whose work spans the operating room, the research lab, and the engineering bench to restore speech and movement for patients who have lost these capabilities. In this episode, Edward explains the evolution of modern neurosurgery and its dramatic reduction in collateral damage, the experience of awake brain surgery, real-time mapping to protect critical functions, and the split-second decisions surgeons make. He also discusses breakthroughs in brain-computer interfaces and functional electrical stimulation systems, strategies for improving outcomes in glioblastoma, and his vision for slimmer, safer implants that could turn devastating conditions like ALS, spinal cord injury, and aggressive brain tumors into more manageable chronic illnesses. We discuss: The evolution of neurosurgery and the shift toward minimally invasive techniques [2:30]; Glioblastomas: biology, current treatments, and emerging strategies to overcome its challenges [10:45]; How brain mapping has advanced from preserving function during surgery to revealing how neurons encode language and cognition [16:30]; How awake brain surgery is performed [22:00]; How brain redundancy and plasticity allow some regions to be safely resected, the role of the corpus callosum in epilepsy surgery, and the clinical and philosophical implications of disconnecting the hemispheres [26:15]; How neural engineering may restore lost functions in neurodegenerative disease, how thought mapping varies across individuals, and how sensory decline contributes to cognitive aging [39:15]; Brain–computer interfaces explained: EEG vs. ECoG vs. single-cell electrodes and their trade-offs [48:30]; Edward's clinical trial using ECoG to restore speech to a stroke patient [1:01:00]; How a stroke patient regained speech through brain–computer interfaces: training, AI decoding, and the path to scalable technology [1:10:45]; Using brain-computer interfaces to restore breathing, movement, and broader function in ALS patients [1:28:15]; The 2030 outlook for brain–computer interfaces [1:34:00]; The potential of stem cell and cell-based therapies for regenerating lost brain function [1:38:00]; Edward's vision for how neurosurgery and treatments for glioblastoma, Parkinson's disease, and Alzheimer's disease may evolve by 2040 [1:42:15]; The rare but dangerous risk of vertebral artery dissections from chiropractic neck adjustments and high-velocity movements [1:44:45]; How Harvey Cushing might view modern neurosurgery, and how the field has shifted from damage avoidance to unlocking the brain's functions [1:46:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Summary of the YouTube Video Featuring Merrill and Andy from Strong Dads and Rock Solid FamiliesIntroduction Update on Merrill's Health•Diagnosis Announcement: Merrill shares that he was diagnosed with glioblastoma on July 23rd, describing it as a severe case with three tumors. The prognosis is uncertain, with varying survival rates depending on treatment efficacy.•Community Support: Merrill expresses deep gratitude for the overwhelming support from the community, including meals, prayers, and financial assistance. He emphasizes the importance of community and church as pillars of support during crises.•Treatment Regimen: Currently undergoing radiation therapy and taking chemotherapy pills, Merrill describes the physical and emotional toll of the treatment, including low energy levels and cognitive challenges.Personal Reflections on Life and Priorities •Emotional Impact: The diagnosis has led Merrill to reassess what is important in life. He stresses the importance of prioritizing relationships, particularly with God, family, and community.•Perspective Shift: Merrill discusses how facing a life-threatening illness has prompted him to reflect deeply on his priorities and what truly matters. He mentions upcoming family events, such as his daughter's wedding, emphasizing the need to cherish these moments.•Faith and Peace: Merrill shares that despite the challenges, he feels a profound sense of peace rooted in his faith. He encourages the audience to consider their relationship with God as a foundational aspect of handling crises.Navigating Relationships and Community •Importance of Relationships: The conversation touches on the significance of nurturing relationships, with God at the center. Merrill highlights how a strong faith can enhance other relationships, particularly with one's spouse.•Joint Efforts in Communication: Merrill and Andy emphasize the need for couples to pray together and communicate effectively, which fosters unity and alignment in facing challenges.Living with Purpose and Prioritizing Faith•Facing Mortality: Merrill reflects on the idea of death and his acceptance of it, grounded in his Christian faith. He expresses anticipation for what lies beyond this life, revealing a lack of fear associated with dying.•Bucket List and Regrets: The discussion shifts towards pursuing dreams and aspirations without fear of failure. Merrill encourages taking risks and being obedient to God's calling, further illustrating this point by discussing his decision to start Rock Solid Families.•Prayer as Communication: Merrill discusses how prayer is not merely about asking for things but about building a relationship with God. He encourages wrestling with God in prayer as a means to deepen that relationship.Conclusion and Call to Action •Final Thoughts: Merrill ends with an encouragement to prioritize faith and community, urging listeners to not take their relationships for granted. He expresses hope that his experience can inspire others to live intentionally.Support the show#Rocksolidfamilies,#familytherapy,#marriagecounseling,#parenting,#faithbasedcounseling,#counseling,#Strongdads,#coaching,#lifecoach,#lifecoaching,#marriagecoaching,#marriageandfamily,#control,#security,#respect,#affection,#love,#purpose,#faith,#mastersofdisaster,#storms,#disasterrelief,#tornados,#hurricanes,#floods

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about a promising blood test to distinguish Parkinson's disease from dementia with Lewy bodies, how CAR T-cell therapies are showing potential for patients with glioblastoma, and a new wireless electroencephalogram device that can even monitor young children with epilepsy.

Grammy-nominated singer, songwriter and pianist Regina Spektor grew up in Soviet Russia, so when she moved to the Bronx with her family in 1990, American food was a bit of a culture shock. Cereal! Oranges! Chocolate pudding cups! It was all brand-new! Regina shares a handful of her family’s immigration eating stories. When in doubt, order the soup! That’s what Regina does. She tells host Rachel Belle about her (nearly) lifelong love of soup, what caused her to rebel against it in high school and why the simplest of broths would be her last meal. Cookbook author Caroline Wright never set out to have a career in soup, but a terminal cancer diagnosis resulted in a soup club, two vegan soup cookbooks and the title of Seattle Soup Lady. She tells Rachel her story. Watch Rachel’s Cascade PBS TV show The Nosh with Rachel Belle! Season 2 out now! Sign up for Rachel’s new (free!) Cascade PBS newsletter for more food musings! Follow along on Instagram! Order Rachel’s cookbook Open Sesame. Support the show: http://rachelbelle.substack.com/See omnystudio.com/listener for privacy information.